<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629364</url>
  </required_header>
  <id_info>
    <org_study_id>KIO-101-2201</org_study_id>
    <nct_id>NCT05629364</nct_id>
  </id_info>
  <brief_title>A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease</brief_title>
  <official_title>A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiora Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiora Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of&#xD;
      KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in&#xD;
      Patients with Autoimmune Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Schirmer's 1 test</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline to Week 12 for Schirmer's 1 test</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>0.15% KIO-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.15% KIO-101 eyedrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% KIO-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3% KIO-101 eyedrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle eyedrops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KIO-101</intervention_name>
    <description>Randomized, Controlled</description>
    <arm_group_label>0.15% KIO-101</arm_group_label>
    <arm_group_label>0.3% KIO-101</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>DHODH inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of autoimmune disease (psoriatic arthritis, Systemic Lupus&#xD;
             Erythematosus (SLE), or fibromyalgia) ≤ 10 years&#xD;
&#xD;
          -  Have an Ocular Discomfort Score (ODS) score of ≥3 at Screening&#xD;
&#xD;
          -  Have an average VAS score ≥ 50 at Screening; and ≥ 40 at Baseline, Visit 2/Day 1&#xD;
&#xD;
          -  Schirmer's 1 test &gt;1 but &lt; 10 mm at Screening.&#xD;
&#xD;
          -  National Eye Institute (NEI) corneal fluorescein staining score of ≥ 4 at Screening&#xD;
             (Day 14) provided that the total NEI score did not change &gt; ± 2 grades from Screening&#xD;
             (Day -14) to Baseline (Day 1) visits, as confirmed by the investigator&#xD;
&#xD;
          -  Have a Best Spectacle Corrected Visual Accuity (BSCVA) score of 20/200 (+1.0 LogMAR)&#xD;
             or better in both eyes at both the Screening and Baseline visits&#xD;
&#xD;
          -  Have a conjunctival hyperaemia score of Grade 2 or more on the Efron Scale in both&#xD;
             eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history or presence of any ocular disorder or condition (other than dry eye&#xD;
             disease (DED)) in either eye that would, in the opinion of the investigator, likely&#xD;
             interfere with the interpretation of the study results or subject safety&#xD;
&#xD;
          -  Have an autoimmune based vasculitis&#xD;
&#xD;
          -  Have a history of RA &gt; 10 years.&#xD;
&#xD;
          -  Have a Schirmer's 1 test score of 0 to 1mm at Screening&#xD;
&#xD;
          -  Have had a corneal transplant in either or both eyes&#xD;
&#xD;
          -  Have had puncta or intracanalicular plug present in either eyelid within 1 year prior&#xD;
             to the Screening Visit or anticipated plug insertion or occlusion at any time during&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>February 21, 2023</last_update_submitted>
  <last_update_submitted_qc>February 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

